Table 1 Demographic, clinical and therapeutic data at the time of an enrollment in IORRA and at the time of measurement of serum 25(OH)D concentration
Factor | At the time of enrollment in IORRA (n = 1957) | At the time of measurement of serum 25(OH)D concentration (spring 2011, n = 899) |
|---|---|---|
Age, years | 57.5 (49.5 to 64.6) | 64.3 (56.7 to 70.6) |
Sex, female | 1668 (85.2) | 766 (87.7) |
Duration of disease, years | 7.0 (2.0 to 14.0) | 16.0 (11.0 to 23.0) |
BMI, kg/m2 | 21.2 (19.4 to 23.3) | 21.2 (19.2 to 23.2) |
DAS28 | 4.2 (3.3 to 5.0) | 3.0 (2.4 to 3.8) |
J-HAQ | 0.8 (0.2 to 1.4) | 0.6 (0.1 to 0.8) |
RF, positive | 1531 (81.8) | 698 (80.0) |
History of smoking, ever | 641 (34.5) | 235 (28.4) |
History of TKR, ever | 85 (4.3) | 178 (20.4) |
DMARDs use, ever | 1670 (85.3) | 777 (89.0) |
Methotrexate use, ever | 792 (40.8) | 638 (73.1) |
Biologic use, ever | 12 (0.6) | 155 (17.8) |
Corticosteroid use, ever | 932 (47.6) | 399 (45.7) |
Bisphosphonate use, ever | 63 (3.2) | 280 (32.1) |
Active vitamin D use, ever | 61 (3.1) | 112 (12.8) |
Serum total protein level, g/dL | Data not available | 7.3 (7.0 to 7.6) |
Serum total cholesterol level, mg/dL | Data not available | 209.0 (188.0 to 231.0) |
Serum alkaline phosphate level, IU/L | Data not available | 258.0 (213.0 to 321.2) |
NSAIDs use, ever | Data not available | 515 (59.0) |